Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed ...

The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...

Basel: Novartis has announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. With the ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus"). With ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 ...

Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. ("Regulus").

Novartis has announced the expiration of its tender offer to acquire Regulus Therapeutics Inc., marking a significant step ...

Bhatt was just 26 when she was diagnosed with polycystic kidney disease (PKD)—a condition she discovered by chance while ...

Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.

DelveInsight's Polycystic Kidney Disease Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Polycystic Kidney Disease treatment.

This study included 615 patients with ADPKD (mean age 48 years, 58.2% female). Of these, 105 patients (17.1%) were taking tolvaptan , a vasopressin V2 receptor antagonist, for an average of 6.1 ...

Investigators in Korea recently designed a study to examine the clinical characteristics and outcomes of kidney transplantation in patients with autosomal dominant polycystic kidney disease ...